Clinical Trial Update: Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and tolerability results for subcutaneous efgartigimod PH20 in Generalized Myasthenia Gravis have been reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Vyvgart (efgartigimod alfa) (efgartigimod alfa)

Snippet

Sponsor: argenx | Conditions: Generalized Myasthenia Gravis | Phase 3 | Status: COMPLETED | Results posted: 2026-01-22